This approach could allow for choosing ROS-elevating or ROS-depleting therapy specific to particular types of cancer cells; (ii) the ROS contribution to ICIs therapy in controlling immune checkpoints such as PD-(L)1 and CTL-4 expressed on cancer cells in immunosuppressive TME; (iii) the contribution of the ROS-associated drug to the interplay between tumor hypoxia and PD-L1 expression; (iv) the administration of nanoparticles as targeted delivery systems to specifically provide ROS over-generation in immunosuppressive TME without generating side effects. Here, SLC44A4 is linked to cancer.